Neurocrine to acquire Soleno Therapeutics for $2.9 billion
Neurocrine Biosciences announced on Monday that it will acquire Soleno Therapeutics for $2.9 billion in cash, marking a strategic expansion into treatments for metabolic disorders. The deal includes a $53 per share offer, representing a roughly 34% premium over Soleno’s previous closing price.
The acquisition provides Neurocrine access to Vykat XR, the first U.S.-approved drug for hyperphagia associated with Prader-Willi syndrome, a rare genetic disorder characterized by intense and persistent hunger. The condition often leads to severe obesity and may cause physical, cognitive, and behavioral challenges.
Soleno’s shares surged over 30% in premarket trading following initial reports of the deal before trading was temporarily halted. The acquisition reflects Neurocrine’s ongoing focus on expanding its portfolio in neuroscience and rare disease treatments.
-
23:00
-
22:30
-
22:00
-
21:30
-
21:00
-
20:30
-
20:00
-
19:30
-
19:00
-
18:30
-
18:00
-
17:30
-
17:15
-
17:00
-
16:30
-
16:00
-
15:30
-
15:19
-
15:15
-
15:00
-
14:30
-
14:15
-
14:00
-
13:40
-
13:25
-
13:10
-
12:55
-
12:40
-
12:25
-
12:10
-
11:50
-
11:42
-
11:35
-
11:20
-
11:17
-
11:16
-
11:05
-
10:50
-
10:49
-
10:35
-
10:20
-
10:08
-
10:05
-
09:57
-
09:50
-
09:35
-
09:20
-
09:15
-
09:05
-
08:50
-
08:35
-
08:20
